Bubs is starting to bear an uncanny resemblance to the good old days of A2M.

The most recent 4C makes for very enjoyable reading with an exploding quarterly revenue of 108% on a pcp basis, and even more impressively 56% on previous quarter.

The Daigou market is the lead indicator for success in China and this is flashing green, green green. They have an equity share deal inked with Chemist warehouse to push product in Oz and CW also has an online presence in China with a T-mall shop.

Regulatory headwinds are likely to be minimal in China because the manufacturing facility they have just bought (Deloraine) is CNCA approved. PLUS Bubs has a major equity investment from C2C partneres which is a subsiduary of Alibaba (which handily owns T-mall)

There is AUD$23 mill in the bank and if you strip out the acquisition costs of Deloraine is cash flow positive if last quarter's sales can be sustained.